Role of cyclic tertiary amine bioactivation to reactive iminium species: Structure toxicity relationship

Current Drug Metabolism

Volumn 12, Issue 1, 2011, Pages 35-50

  Mašič, Lucija Peterlin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Bioactivation; Cyanide; Cyclic tertiary amines; Glutathione; Iminium ion; P450; Reactive metabolite; Structural alert

Indexed keywords

8 HYDROXYMIANSERIN; ARIPIPRAZOLE; CYTOCHROME P450 2D6; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLITE; ESTROGEN; GLUTATHIONE; HALOPERIDOL; IMINE; LOPERAMIDE; MB 243; MIANSERIN; MIANSERIN N OXIDE; MONOAMINE OXIDASE B INHIBITOR; N DESMETHYLMIANSERIN; N METHYL TETRAHYDROQUINOLINE; NEFAZODONE; NICOTINE; NOMIFENSINE; PHENCYCLIDINE; PIPERAZINE DERIVATIVE; PRAZOSIN; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN 2C AGONIST; TERTIARY AMINE; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD DYSCRASIA; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG ERUPTION; DRUG METABOLISM; DRUG STRUCTURE; ERECTILE DYSFUNCTION; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; LIVER TOXICITY; MENOPAUSAL SYNDROME; NEUROTOXICITY; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARKINSONISM; SCHIZOPHRENIA; STRUCTURE TOXICITY RELATION; SYNCOPE; TARDIVE DYSKINESIA; TOXICITY; UNSPECIFIED SIDE EFFECT;

AMINES; ANIMALS; BIOTRANSFORMATION; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PYRROLIDINES; XENOBIOTICS;

EID: 79951660456     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011794520044     Document Type: Article

References (85)

1. Amacher, D. E. Reactive intermediates and the pathogenesis of adverse drug reactions: The toxicology perspective. Curr. Drug Metab., 2006, 7, 219-229.
2. Kalgutkar, A. S. In: Advances in Bioactivation Research; A. A. Elfarra, Ed.; American Association of Pharamceutical Scientists, 2008; pp. 27-55.
3. Hollenberg, P. F.; Kent, U. M.; Bumpus, N. N. Mechanism-Based Inactivation of Human Cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol., 2008, 21, 189-205. (Pubitemid 351219719)
4. Lasser, K. E.; allen, P. D.; Woolhandler, S. J.; Himmelstein, D. U.; Wolfe, S. M.; Bor, D. H. Timing of new black box warning and withdrawals for prescription medications. J. Am. Med. Assoc., 2002, 287, 2215-2220. (Pubitemid 34441937)
5. Kalgutkar, A. S.; Fate, G.; Didiuk, M. T.; Bauman, J. Toxicophores, reactive metabolites and drug safety: when is it a cause for concern? Exp. Rev. Clin. Pharmacol., 2008, 1, 515-531.
6. Kumar, S.; Kassahun, K.; Tschirret-Guth, R. A.; Mitra, K.; Baillie, T. A. Minimizing metabolic activation during pharmaceutical lead optimisation: progress, knowledge gaps and future directions. Curr. Opin. Drug Discov., 2008, 11, 43-52.
7. Castagnoli, Jr., N.; Rimoldi, J. M.; Bloomquist, J.; Castagnoli, K. P. Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. Chem. Res. Toxicol., 1997, 10, 924-940. (Pubitemid 27418007)
8. Gorrod, J. W.; Aislaitner, G. The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur. J. Drug Metab. Phatmacokinet., 1994, 19, 209-217. (Pubitemid 24331190)
9. Kalgutkar, A. S.; Dalvie, D. K.; O'Donnell, J. P.; Taylor, T. J.; Sahakian, D. C. On the diversity of oxidative bioactivation reactins on nitrogen-containing xenobiotics. Curr. Drug Metab., 2002, 3, 379-424. (Pubitemid 34778004)
10. Sayre, L. M.; Engelhart, D. A.; Nadkarni, D. V.; Babu, M. K. M.; Klein, M. E.; McCoy, G. Haemoprotein-mediated metabolism of enamines and the possible involvement of one-electron oxidations. Xenobiotica, 1995, 7, 769-775.
11. Maret, G.; Testa, B.; Jenner, P.; El Taya, N.; and Carrupt, P-A. The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing Parkinsonism. Drug Metab. Rev., 1990, 22, 291-332. (Pubitemid 20340902)
12. Gerlach, M.; Riederer, P.; Przuntek, H.; Youdim, M. B. H. MPTP mechanism of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol., 1991, 208, 273-286.
13. Di Monte, D. A.; Royland, J. E.; Irwin, I.; Langston, J. W. Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology, 1996, 17, 697-704. (Pubitemid 27131818)
14. Castagnoli, N. Jr.; Castagnoli, K.; Magnin, G.; Kuttab, S.; Shang, J. Studies on the oxidation of 1, 4-disubstituted-1, 2, 3, 6-tetrahydropyridines. Drug. Metab. Rev., 2002, 34, 533-547.
15. Barsoum, N.j.; Gouh, A. W.; Sturgess, J. M.; De la Iglesia, F. W. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivatives. Neurotoxicology, 1986, 7, 119-126. (Pubitemid 16116626)
16. Taylor, C. P.; Sedman, A. J. In: Transmitter Amino Acid Receptors: Structures, Transduction And Models For Drug Development: Bernard, E. A. and Costa, E, Eds., Thieme Medical Publishers, New York, 1991, pp. 251-271.
17. Radulovic, L.; Woolf, T.; Bjorge, S.; Taylor, C.; Reiley, M.; Bockbrader, H.; Chang, T. Identification of a pyridinium metabolite in human urine following a single oral dose of 1-[2-[bis[4-(trifluoromethyl) phenyl]methoxy]ethyl]-1, 2, 5, 6-tetrahydro-3-pyridinecarboxylic acid monohydrochloride (CI-966), a.gamma.-aminobutyric acid uptake inhibitor. Chem. Res. Toxicol., 1993, 6, 341-344. (Pubitemid 23146597)
18. Amit S. Kalgutkar, Sue Zhou, Odette A. Fahmi, Timothy J. Taylor. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1, 2, 3, 6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6. Drug Metab. Dispos., 2003, 31, 596-605. (Pubitemid 36444169)
19. Jurva, U.; Bissel, P.; Isin, E. M.; Igarashi, K.; Kuttab, S.; Castagnoli, N. Jr. Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines. J. Am. Chem. Soc. 2005, 127, 12368-12377. (Pubitemid 41279264)
20. Naisbitt, D. J.; Williams, D. P.; Pirmohamed, M.; Kitteringham, N. R.; and Park, B. K. Reactive metabolites and their role in drug reactions. Curr. Opin. Allergy Clin. Immunol, 2001, 1, 317-325.
21. Chen, W. G.; Zhang, C.; Avery, M. J.; Fouda, H. G. Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv. Exp. Med. Biol., 2001, 500, 521-524. (Pubitemid 34107049)
22. Johnson, B. M.; and van Breemen, R. B. In vitro formation of quinoid metabolites of the dietary supplement Cimicifuga racemosa (black cohosh). Chem. Res. Toxicol, 2003, 16, 838-846. (Pubitemid 36898998)
23. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and oquinones. Chem. Res. Toxicol, 2004, 17, 879-888. (Pubitemid 38955346)
24. Castro-Perez, J.; Plumb, R.; Liang, L.; Yang, E. A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun. Mass Spectrom., 2005, 19, 798-804. (Pubitemid 40349420)
25. Ketterer, B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat. Res., 1988, 202, 343-361.
26. Baillie, T. A.; Davis, M. R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom., 1993, 22, 319-325. (Pubitemid 23165443)
27. Grillo, M. P.; Hua, F.; Knutson, C. G.; Ware, J. A.; and Li, C. Mechanistic studies on the bioactivation of diclofenac: identification of diclofenac-S-acyl-glutathione in vitro in incubations with rat and human hepatocytes. Chem. Res. Toxicol., 2003, 16, 1410-1417. (Pubitemid 37464462)
28. Argoti, D.; Liang, L.; Conteh, A.; Liangfu Chen, L.; Bershas, D.; Yu, C. P.; Vouros, P.; Yang, E. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem. Res. Toxicol., 2005, 18, 1537-1544. (Pubitemid 41504473)
29. Gorrod, J. W.; Whittlesea, C. M.; Lam, S. P. Trapping of reactive intermediates by incorporation of 14C-sodium cyanide during microsomal oxidation. Adv. Exp. Med. Biol., 1991, 283, 657-664.
30. Meneses-Lorente, G.; Zea Sakatis, M.; Schulz-Utermoehl, T.; De Nardi, C.; Watt, A. P. A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal. Biochem., 2006, 351, 266-272.
31. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; and Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol, 2004, 17, 3-16. (Pubitemid 38134055)
32. Zhang, Z.; Chen, Q.; Li, Y.; Doss, G. A.; Dean, B. J.; Ngui, J. S.; Elipe, M. S.; Kim, S.; Wu, J. Y.; DiNinno, F.; Hammond, M. L.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W. In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites. Chem. Res. Toxicol, 2005, 18, 675-685. (Pubitemid 40563281)
33. Williams, D. A.; Lemke, T. L. Foye's Principles of Medicinal Chemistry, 5th ed.; Lippincott Williams & Wilkins; Philadelphia, 2002.
34. Palucki, B. L.; Park, M. K.; Nargund, R. P.; Ye, Z.; Sebhat, I. K.; Pollard, P. G.; Kalyani, R. N.; Tang, R.; MacNeil, T.; Weinberg, D. H.; Vongs, A.; Rosenblum, C. I.; Doss, G. A.; Miller, R. R.; Stearns, R. A.; Peng, Q.; Tamvakopoulos, C.; McGowan, E.; Martin, W. J.; Metzger, J. M.; Shepherd, C. A.; Strack, A. M.; MacIntyre, D. E.; Van der Ploeg, L. H. T.; Patchett, A. A. Discovery of (2S)-N-[(1 R)-2-[4-cyclohexyl-4-[[(1, 1-dimethylethyl) amino] carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl) methyl]-2-oxoethyl]-4-methyl-2- piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett., 2005, 15, 171-175. (Pubitemid 39575806)
35. Doss, G. A.; Miller, R. R.; Zhang, Z.; Teffera, Y.; Nargund, R. P.; Palucki, B.; Park, M. K.; Tang, Y. S.; Evans, D. C.; Baillie, T. A.; Stearns, R. A. Metabolic Activation of a 1, 3-Disubstituted Piperazine Derivative: Evidence for a Novel Ring Contraction to an Imidazoline. Chem. Res. Toxicol., 2005, 18, 271-276. (Pubitemid 40256246)
36. Zeiger, E. Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance. Regul. Toxicol. Pharmacol., 1998, 28, 85-95. (Pubitemid 29076774)
37. Kim, B. S.; Margolin, B. H. Prediction of rodent carcinogenicity utilizing a battery of in vitro and in vivo genotoxicity tests. Environ. Mol. Mutagen., 1999, 34, 297-304. (Pubitemid 30039047)
38. Kalgutkar, A. S.; Dalvie, D. K.; Aubrecht, J.; Smith, E. B.; Coffing, S. L.; Cheung, J. R.; Vage, C.; Lame, M. E.; Chiang, P.; McClure, K. F.; Maurer, T. S.; Coelho, Jr., R. V.; Soliman, V. F.; Schildknegt, K. Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl) pyrazine, a novel 5-hHydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation. Drug. Metab. Dispos., 2007, 35, 848-858. (Pubitemid 46798595)
39. Fava, M.; Dunner, D. L.; Greist, J. H.; Preskorn, S. H.; Trivedi, M. H.; Zajecka, J.; Cohen, M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. J. Clin. Psychiatry, 2001, 62, 413-420. (Pubitemid 32717873)
40. Inman, W. H. W. Safety of midazolam. Lancet, 1988, 2, 683-684.
41. Chow, T.; Hiroi, T.; Imaoka, S.; Chiba, K.; Funae, Y. Isoformselective metabolism of mianserin by cytochrome P-450 2D. Drug. Metab. Dispos., 1999, 27, 1200-1204. (Pubitemid 29463608)
42. Riley, R. J.; Kitteringham, N. R.; Park, B. K. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. Br. J. Clin. Pharmacol., 1989, 28, 482-487. (Pubitemid 19269788)
43. Riley, R. J.; Roberts, P.; Kitteringham, M. R. Park, B. K. Formation of cytotoxic metabolites from phenytoin, imipramine, desipramine, amitriptyline and mianserin by mouse and human hepatic microsomes. Biochem. Pharmacol., 1990, 39, 1951-1958. (Pubitemid 20187331)
44. Wen, B. and Fitch, L. Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trapmass spectrometry J. Mass Spectrometry, 2009, 44, 90-99.
45. Andrade, R. J.; Lucena, M. I. Drug-induced hepatotoxicity. N. Eng.l J. Med., 2003, 349, 1974-1976.
46. Choi, S. Nefazodone (serzone) withdrawn because of hepatotoxicity. CMAJ., 2003, 169, 1187. (Pubitemid 37491525)
47. Kalgutkar, A. S.; Vaz, A. D.; Lame, M. E.; Henne, K. R.; Soglia, J.; Zhao, S. X.; Abramov, Y. A.; Lombardo, F.; Collin, C.; Hendsch, Z. S.; Hop, C. E. C. A. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug. Metab. Dispos., 2005, 33, 243-253. (Pubitemid 40216592)
48. Caccia, S. N-Dealkylation of arylpiprazine derivatives: Disposition and metabolism of the 1-arylpiperazines formed. Curr. Drug. Metab., 2007, 8, 612-622. (Pubitemid 47209098)
49. Bauman, J. N.; Frederick, K. S.; Sawant, A.; Walsky, R. L.; Cox, L. M.; Obach, R. S.; Kalgutkar, A. S. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug. Metab. Dispos., 2008, 36, 1016-1029. (Pubitemid 351717458)
50. Stanaszek, W. F.; Kellerman, D.; Brogden, R. N.; Romankiewicz, J. A. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs, 1983, 25, 339-384. (Pubitemid 13112223)
51. Erve, J. C. L.; Vashishtha, S. C.; DeMaio, W.; Talaat, R. E. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry. Drug. Metab. Dispos., 2007, 35, 908-916. (Pubitemid 46798601)
52. Driscoll, J. P.; Kornecki, K.; Wolkowski, J. P.; Chupak, L.; Kalgutkar, A. S.; O'Donnell, J. P. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: Evidence for the formation of a novel quinone methide intermediate. Chem. Res. Toxicol., 2007, 20, 1488-1497. (Pubitemid 350057218)
53. Sayre, L. M.; Engelhart, D. A.; Venkataraman, B.; Babu, M. K. M.; McCoy, G. D. Generation and fate of enamines in the microsomal metabolism of cyclic tertiary amines. Biocem. Biophy. Res. Comm., 1991, 179, 1368-1376.
54. Masumoto, H.; Ohta, S.; Hirobe, M. Application of chemical cytochrome P-450 model system to studies on drug metabolism. Drug. Metab. Dispos., 1991, 19, 768-778.
55. Ward, D.; Kalir, A.; Trevor, A.; Adams, J. Metabolic formation of iminium species: metabolism of phencyclidine. J. Med. Chem., 1982, 25, 491-492. (Pubitemid 12051969)
56. Baker, J. K.; Little, T. L. Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. J. Med. Chem., 1985, 28, 46-50. (Pubitemid 15156295)
57. Jushchyshyn, M. I.; Kent, U. M.; Hollenberg, P. F. The mechanismbased inactivation of human cytochrome P450 2B6 by phencyclidine. Drug. Metab. Dispos., 2003, 31, 46-52. (Pubitemid 36735257)
58. Dutertre, M.; and Smith, C. L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J. Pharmacol. Exp. Ther., 2000, 295, 431-437.
59. Bolton, J. L.; Trush, M. A.; Penning, T. M.; Dryhurst, G.; Monks, T. J. Role of quinones in toxicology. Chem. Res. Toxicol, 2000, 13, 135-160. (Pubitemid 30169958)
60. Kim, S., Wu, J. Y., Birzin, E. T., Frisch, K., Chan, W., Pai, L., Yang, Y. T., Mosley, R. T., Fitzgerald, P. M. D., Sharma, N., Dahllund, J., Thorsell, A., Dininno, F., Rohrer, S. P., Schaeffer, J. M., Hammond, M. L. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor a modulators. J. Med. Chem., 2004, 47, 2171-2175. (Pubitemid 38478840)
61. Kim, S.; Wu, J.; Chen, H. Y.; Birzin, E. T.; Chan, W.; Yang, Y. T.; Colwell, L.; Li, S.; Dahllund, J.; Dininno, F.; Rohrer, S. P.; Schaeffer, J. M.; Hammond, M. L. Estrogen receptor ligands. Part 4. The SAR of the syn-dihydrobenzoxathiin SERMs. Bioorg. Med. Chem. Lett., 2004, 14, 2741-2745. (Pubitemid 38569730)
62. Zhang, Z.; Chen, Q.; Li, Y.; Doss, G. A.; Dean, B. J.; Ngui, J. S.; Elipe, M. S.; Wu, S. K. J. Y.; DiNinno, F.; Hammond, M. L.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W. In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites. Chem. Res. Toxicol, 2005, 18, 675-685. (Pubitemid 40563281)
63. Rang, J.; Gorrod, J. W. E. Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol. Lett., 1991, 59, 117-123.
64. Kalgutkar, A. S.; Nguyen, H. T. Identification of N-methyl-4- phenylpyridinium-like metabolite of the antidarrheal agent loperamide in human liver microsomes: undelying reason (s) for the lack of neurotoxicity despite the bioactivation event. Drug. Metab. Dispos., 2004, 32, 943-952. (Pubitemid 39096054)
65. Augustyns, K. J. L.; Lambeir, A. M.; Borloo, M.; De Meester, I.; Vedernikova, I.; Vanhoof, G.; Hendriks, D.; Scharpé, S.; Haemers, A. Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur. J. Med. Chem., 1997, 32, 301-309. (Pubitemid 27220261)
66. Caldwell, C. G.; Chen, P.; He, J.; Parmee, E. R.; Leiting, B.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Eiermann, G. J.; Petrov, A. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 1265-1268 (Pubitemid 38229869)
67. Shiyao Xu, Bing Zhu, Yohannes Teffera, Deborah E. Pan, Charles G. Caldwell, George Doss, Ralph A. Stearns, David C. Evans, Maria G. Beconi. Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug. Metab. Dispos., 2005, 33, 121-130. (Pubitemid 40023523)
68. Fowler, J. S.; Volkow, N. D.; Wang, G-J.; Pappas, N.; Logan, J.; MacGregor, R.; Alexoff, D.; Shea, C.; Schlyer, D.; Wolf, A. P.; Warner, D.; Zezulkova, I.; Cilento, R. Inhibition of monoamine oxidase B in the brains of smokers. Nature, 1996, 379, 733-736. (Pubitemid 26061736)
69. Liu, X.; Zang, L.;. Van der Schyf, C. J.; Igarashi, K.; Castagnoli, K.; Castagnoli, Jr. N. Studies on the pyrrolinone metabolites derived from the tobacco alkaloid 1-methyl-2-(3-pyridinyl) pyrrole (pnicotyrine). Chem. Res. Toxicol, 1999, 12, 508-512. (Pubitemid 29282921)
70. Liu, X.; Castagnoli, K.; Van der Schyf, C. J.; Castagnoli, Jr. N. Studies on the in vivo biotransformation of the tobacco alkaloid (3-nicotyrine. Chem. Res. Toxicol, 2000, 13, 336-341. (Pubitemid 30327152)
71. Booth, R. G.; Castagnoli,. N Jr.; Rollema, H. Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+. Neurosci. Lett., 1989, 100, 306-312. (Pubitemid 19128194)
72. Holsworth, D. D.; Powell, N. A.; Downing, D. M.; Cai, C.; Cody, W. L.; Ryan, J. M.; Ostroski, R.; Jalaie, M.; Bryant, J. W.; Edmunds, J. J. Discovery of novel non-peptidic ketopiperazine-based renin inhibitors. Bioorg. Med. Chem., 2005, 13, 2657-2664. (Pubitemid 40341668)
73. Holsworth, D. D.; Cai, C.; Cheng, X.; Cody, W. L.; Downing, D. M.; Erasga, N.; Lee, C.; Powell, N. A.; Edmunds, J. J.; Stier, M. Ketopiperazine-based renin inhibitors: optimization of the "C" ring. Bioorg. Med. Chem. Lett., 2006, 16, 2500-2504.
74. Gu, G.; Collins, R.; Holsworth, D. D.; Walker, G. S.; Voorman, R. L. Metabolic aromatization of N-alkyl-1, 2, 3, 4-tetrahydroquinoline substructures to quinolinium by human liver microsomes and horseradish peroxidase. Drug Metab. Dispos., 2006, 34, 2044-2055. (Pubitemid 44837765)
75. Salama, A.; Mueller-Eckhardt, C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N. Engl. J. Med., 1985, 313, 469-474. (Pubitemid 15015074)
76. Stonier, P. D.; Edwards, J. G. Nomifensine And Haemolytic Anemia, In Pharmacovigilance; Mann, R. D.; Andrews, E. B. eds), 2002; pp. 155-166, Wiley, New York.
77. Obach, R. S.; Dalvie, D. K. Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes. Drug Metab. Dispos., 2006, 34, 1310-1316. (Pubitemid 44079871)
78. Kam, P. C. A.; Nethery, C. M. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia, 2003, 58, 28-35. (Pubitemid 36113325)
79. Noble, S.; Goa, K. L. Ticlopidine: a review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischemia and stroke. Drugs Aging., 1996, 8, 214-232.
80. Dalvie, D. K.; O'Connell, T. N. Characterisation of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab. Dispos., 2004, 32, 49-57. (Pubitemid 38112535)
81. Baillie, T. A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol., 2008, 21, 129-137. (Pubitemid 351219714)
82. Kalgutkar, A. S.; Gardne, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6, 161-225. (Pubitemid 40753853)
83. Chen, Q.; Ngui, J. S.; Doss, G. A.; Wang, R. W.; Cai, X.; DiNinno, F. P.; Blizzard, T. A.; Hammond, M. L.; Stearns, R. S.; Evans, D. C.; Baillie, T. A.; Tang, W. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol., 2002, 15, 907-914. (Pubitemid 34774444)
84. Yu, L.; Liu, H.; Li, W.; Zhang, F.; Luckie, C.; van Breemen, R. B.; Thacher, G. R. J.; Bolton, J. L. Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem. Res. Toxicol., 2004, 17, 879-888. (Pubitemid 38955346)
85. Dowers, T. S.; Qin, Z. H.; Thatcher, G. R. J.; Bolton, J. L. Bioactivation of selective estrogen receptor modulators (SERMs). Chem. Res. Toxicol., 2006, 19, 1125-1137. (Pubitemid 44454028)